Metformin for overweight women at midlife: A double-blind, randomized, controlled trial

Climacteric

Volumn 18, Issue 2, 2015, Pages 270-277

  Worsley, R ^a   Jane, F ^a   Robinson, P J ^a   Bell, R J ^a   Davis, S R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Insulin resistance; metformin; obesity; women

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; LIPID; SEX HORMONE BINDING GLOBULIN;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL OF ASSESSMENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MODEL; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; AGED; ANALYSIS; BLOOD; DIET RESTRICTION; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; DOUBLE-BLIND METHOD; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPIDS; METFORMIN; MIDDLE AGED; OBESITY; SEX HORMONE-BINDING GLOBULIN; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 84924726307     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.954997     Document Type: Article

References (35)

1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766-81
2. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and infl ammation in metabolic homeostasis. Science 2013; 339: 172-7
3. Davis S R, C astelo-Branco C, C hedraui P, et a l. U nderstanding weight gain at menopause. Climacteric 2012; 15: 419-29
4. Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005; 54: 2404-14
5. Calanna S, S cicali R, D i Pino A, et a l. A lpha-and beta-cell abnormalities in haemoglobin A1c-defi ned prediabetes and type 2 diabetes. Acta Diabetol 2014; 51: 567-75
6. Stumvoll M, Haring HU, Matthaei S. Metformin. Endocrine Res 2007; 32: 39-57
7. Knowler WC, Barrett-Connor E, Fowler SE, et a l. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
8. Moghetti P, C astello R, N egri C, e t a l. M etformin effects on clinical features, endocrine and metabolic profi les, and insulin sensitivity in polycystic ovary syndrome: a randomised double-blind, placebo-controlled 6-month trial, followed by open long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139-46
9. Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother 2008; 42: 817-26
10. McInnes K J, Corbould A, S impson E R, J ones M E. R egulation of adenosine 5 ',monophosphate-activated protein kinase and lipogenesis by androgens contributes to visceral obesity in an estrogen-defi cient state. Endocrinology 2006; 147: 5907-13
11. Franklin R M, P loutz-Snyder L, K analey J A. L ongitudinal changes in abdominal fat distribution with menopause. Metabolism 2009; 58: 311-15
12. Moher D, H opewell S, S chulz K F, e t a l. C ONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c869
13. Harlow S D, Gass M, H all J E, e t a l. E xecutive summary of the Stages of Reproductive Aging Workshop 10: addressing the unfi nished agenda of staging reproductive aging. Climacteric 2012; 15: 105-14
14. Afzal S, Bojesen SE, Nordestgaard BG. Low 25-hydroxyvitamin D and risk of type 2 diabetes: a prospective cohort study and metaanalysis. Clin Chem 2013; 59: 381-91
15. Holick M F, B inkley N C, B ischoff-Ferrari H A, et a l. E valuation, treatment, and prevention of vitamin D defi ciency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-30
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19
17. Davis S R, S tuckey B G, N orman R J, P apalia M A, D rillich A, Bell RJ. Effects of the route of estrogen administration on insulin like growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study. Menopause 2008; 15: 1065-9
18. McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of the benefi ts and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr 2014; 168: 178-84
19. Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008; 299: 185-93
20. Glintborg D, A ltinok ML, M umm H, H ermann AP, R avn P, Andersen M. Body composition is improved during 12 months ' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab 2014; 99: 2584-91
21. Stern S E, W illiams K, F errannini E, D eFronzo R A, B ogardus C, Stern MP. Identifi cation of individuals with insulin resistance using routine clinical measurements. Diabetes 2005; 54: 333-9
22. Zhang X, G regg EW, Williamson DF, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care 2010; 33: 1665-73
23. Gayoso-Diz P, O tero-Gonzalez A, R odriguez-Alvarez M X, e t a l. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord 2013; 13: 47
24. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012; 35: 731-7
25. Wang M, Tong JH, Zhu G, Liang GM, Yan HF, Wang X Z. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. Schizophrenia Res 2012; 138: 54-7 Love-Osborne
26. K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modifi cation program in adolescents with insulin resistance. J Pediatr 2008; 152: 817-22
27. Srinivasan S, Ambler GR, Baur LA, et al. R andomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006; 91: 2074-80
28. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 1999; 48: 511-19
29. Gambineri A, Pelusi C, Genghini S, et al. Effect of fl utamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol 2004; 60: 241-9
30. Lord J, T homas R, F ox B, A charya U, W ilkin T. T he effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome-a randomised, doubleblind, placebo-controlled trial. BJOG 2006; 113: 817-24
31. Pau CT, Keefe C, Duran J, Welt CK. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an openlabel, interventional study. J Clin Endocrinol Metab 2014; 99: 1870-8
32. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II noninsulin-dependent diabetes. Obes Res 1998; 6: 47-53
33. Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signalling. J Mol Endocrinol 2010; 44: 87-97
34. Aubert G, M ansuy V, V oirol M J, P ellerin L, P ralong FP. T he anorexigenic effects of metformin involve increases in hypo thalamic leptin receptor expression. Metabolism 2011; 60: 327-34
35. Cersosimo E, S olis-Herrera C, T rautmann M E, M alloy J, Triplitt CL. Assessment of pancreatic beta-cell function: review of methods and clinical applications. Curr Diabetes Rev 2014; 10: 2-42